BSXHealthcare · Medical DevicesThe 31 Wall Street analysts covering Boston Scientific Corp. hold a median 12-month price target of $60 — +34.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 23 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Boston Scientific Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (5): The shares have been drifting down relative to others.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BSX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.3% from it.
Of the 20 most recent actions, 0 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Sept 2026 | Oppenheimer | Maintains | Outperform | $85 → $65 |
| 17 Sept 2026 | Citigroup | Downgrade | Neutral | $57 → $50 |
| 9 Sept 2026 | BTIG | Maintains | Buy | — |
| 9 Sept 2026 | BTIG | Maintains | Buy | $60 → $56 |
| 25 Aug 2026 | TD Cowen | Reiterates | Buy | $56 |
| 25 Aug 2026 | TD Cowen | Reiterates | Buy | — |
| 31 July 2026 | Argus Research | Downgrade | Hold | — |
| 31 July 2026 | Argus Research | Downgrade | Hold | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $70 → $66 |
| 30 July 2026 | Citigroup | Maintains | Buy | $70 → $61 |
| 30 July 2026 | Citigroup | Maintains | Buy | — |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | $65 → $55 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | $85 → $70 |
| 30 July 2026 | RBC Capital | Maintains | Outperform | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | $61 → $56 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $62 → $57 |
| 30 July 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BSX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Boston Scientific Corp. returned −54.4% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 40% of US stocks
Cheaper than 37% of US stocks
Cheaper than 26% of US stocks
Higher than 45% of US stocks
Higher than 52% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 80% of US stocks
Higher than 75% of US stocks
Higher than 82% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Boston Scientific Corp. has a market value of $65.1B and an enterprise value of $77.4B.
Revenue in the twelve months to 30 June 2026: $21.0B. The latest quarter grew 7.5% year on year.
Net income over the same four quarters: $3.7B, a 17.5% net margin.
Diluted earnings per share, trailing twelve months: $2.47.
Free cash flow in the twelve months to 30 June 2026: $1.8B.
Trailing P/E: 17.9×; forward P/E: 13.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Boston Scientific Corp. employs 59,000 people — $356K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Boston Scientific Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reports that Boston Scientific's upcoming product launches, including SEISMIQ 4CE and FARAFLEX, are likely to provide new growth opportunities across its key businesses.
Why it matters — BSX watchers would care because these upcoming launches could shape the company's next phase of growth across its key business segments.
On September 21st, 2026, Zacks Investment Research added BSX, along with AGCO and AEG, to its Zacks Rank #5 (Strong Sell) List.
Why it matters — A Zacks Strong Sell rating signals a bearish analyst outlook that a BSX watcher may want to take into account.
Boston Scientific faces near-term pressure in its electrophysiology business, while competitor Medtronic gains share and shows stronger momentum across key franchises, according to a Zacks comparison of the two stocks.
Why it matters — BSX watchers would care because it flags competitive pressure in the electrophysiology segment, a key growth area for the company.
Zacks Investment Research added Boston Scientific Corp. (BSX) to its Zacks Rank #5 (Strong Sell) List on September 16th, 2026, along with AGCO and BBWI. The move places BSX on the firm's list of stocks expected to underperform.
Why it matters — A BSX watcher would care because a Strong Sell ranking from Zacks signals a negative near-term outlook for the company's stock.
Seeking Alpha upgraded Boston Scientific to 'Strong Buy', describing the stock's valuation as deeply discounted relative to its historical average following a market overreaction. The analysis cites solid Q2 2026 results with WATCHMAN and electrophysiology headwinds offset by momentum in Interventional Cardiology and Vascular Therapies.
Why it matters — The rating upgrade highlights an analyst view that BSX's current valuation presents an attractive entry point for long-term investors despite mixed segment performance.
The 31 Wall Street analysts covering Boston Scientific Corp. have a median 12-month price target of $60, with estimates ranging from $44 to $94. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 31 analysts covering Boston Scientific Corp., 25 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boston Scientific Corp. 56 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Boston Scientific Corp. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
No one can know that. What the data says: the median 12-month target from 31 analysts implies +34.3% from the last close, and Ticker Nerd's factor model ranks Boston Scientific Corp. 56 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Boston Scientific Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $94 over the next 12 months.
Boston Scientific Corp. returned -54.4% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide.
The most recent item we track (Zacks Investment Research, 21 Sept 2026): "Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?". Zacks Investment Research reports that Boston Scientific's upcoming product launches, including SEISMIQ 4CE and FARAFLEX, are likely to provide new growth opportunities across its key businesses.
Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology, and neuromodulation. Its MedSurg segment covers products for digestive health, urinary care, and pain management, while its Cardiovascular segment supports minimally invasive treatment options for heart and vascular conditions. Boston Scientific’s devices are designed to help healthcare professionals diagnose and treat patients through less invasive approaches across hospitals, clinics, and specialized medical centers. Headquartered in Marlborough, Massachusetts, Boston Scientific plays a significant role in the global health care equipment market through its broad mix of procedure-based products and physician-focused solutions.
CEO Mr. Michael F. Mahoney · 59,000 employees · United States · https://www.bostonscientific.com
